AbbVie (NYSE:ABBV) Shares Down 2.5% – What’s Next?

AbbVie Inc. (NYSE:ABBV) was down 2.5% during trading on Monday . The stock traded as low as $244.44 and last traded at $244.6180. Approximately 7,287,556 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 7,042,114 shares. The stock had previously closed at $250.94.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong growth outlook: AbbVie raised its 2026 revenue guidance, supported by continued momentum from immunology drugs Skyrizi and Rinvoq as well as growth in neuroscience. Second-quarter revenue rose 10.2% year over year to $16.99 billion, while adjusted EPS of $3.65 exceeded the $3.61 consensus estimate. ABBV Q2 Earnings Call Balances Growth With Apogee Dilution
• Positive Sentiment: Analyst support increased: Cantor Fitzgerald raised its AbbVie price target from $265 to $285 and maintained an “overweight” rating, signaling confidence in the company’s growth prospects and pipeline. Cantor Fitzgerald Raises AbbVie Price Target
• Positive Sentiment: Pipeline optionality: AbbVie’s late-stage ABBV-706 study in small-cell lung cancer and its telisotuzumab adizutecan antibody-drug conjugate could add future oncology growth if clinical trials succeed. AbbVie’s ABBV-706 Lung Cancer Trial
• Neutral Sentiment: Healthcare and other value-oriented sectors are attracting interest as technology stocks weaken, potentially supporting defensive pharmaceutical names and value ETFs holding ABBV. The S&P 493 Are Staging a Comeback
• Negative Sentiment: Apogee acquisition weighs on near-term earnings: The deal is expected to reduce 2026 EPS guidance and increase R&D expenses, creating dilution despite the higher revenue outlook. This has contributed to the post-earnings weakness in ABBV. AbbVie Q2 2026 Earnings: Profit Forecast Cut for Apogee Deal

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ABBV shares. BMO Capital Markets increased their price objective on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company upped their target price on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. HSBC reissued a “buy” rating and issued a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Finally, Bank of America boosted their price objective on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $271.48.

AbbVie Stock Performance

The company has a market cap of $432.19 billion, a P/E ratio of 69.10, a P/E/G ratio of 0.83 and a beta of 0.30. The stock has a 50-day simple moving average of $239.10 and a 200 day simple moving average of $224.08.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 466.39% and a net margin of 9.80%.AbbVie’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.12 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Hedge Funds Weigh In On AbbVie

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Litman Gregory Wealth Management LLC acquired a new position in AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie in the 4th quarter worth about $31,000. Finally, WestEnd Advisors LLC increased its position in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.